Inadequate analytical development and process validation pose significant challenges for advanced therapies. Finding expert partners with the necessary skills to optimize AAV processes is crucial for minimizing variability and risk. Explore key considerations for advancing your AAV gene therapy from concept to commercialization, leveraging the power of advanced analytics.
Cell and gene therapies are increasingly popular vehicles for treating rare diseases. However, viral vector expertise is hard to come by and can make a difference in advancing a therapy to market. As you search for the right CDMO to manufacture your AAV therapy, start early and place a major premium on previous experience.
Adeno-associated virus (AAV) has become an increasingly popular vector for gene therapy applications, yet ongoing challenges related to process and analytical development often require significant expertise to navigate. Success with these vectors necessitates a flexible, balanced analytical approach that is scale-appropriate and can be adapted to a product's evolving needs.
To address the myriad of challenges that accompany AAV manufacturing, Andelyn uses a combination of reductionist and holistic approaches to perform end-to-end optimization for its platform. The end-result is a platform with process steps that are modular with options that can be tailored to a project's specific needs.
With the highest quality standards and scalable end-to-end development and manufacturing capabilities across its Columbus, Ohio facilities, Andelyn is enabling the progression of life-altering gene therapies for rare and prevalent diseases. Learn more.
This website uses cookies to ensure you get the best experience on our website. Learn more
